Authors: Damato, Bertil; Coupland, Sarah E

Source: Expert Review of Anticancer Therapy, Volume 9, Number 9, September 2009 , pp. 1227-1239(13)

Publisher: Expert Reviews

Abstract:

Invasive conjunctival melanoma can arise de novo, from nevus or from melanoma in situ. The literature reports that after treatment of invasive conjunctival melanoma more than 50% of patients develop local tumor recurrence, with 20% eventually requiring orbital exenteration and 20-30% developing fatal metastasis. Our results have improved since we replaced adjuvant cryotherapy with radiotherapy and topical chemotherapy. There is scope for multicenter clinical trials and translational research, but these require consistent staging and grading of disease. We propose that the term `primary acquired melanosis' should only be used clinically, when the histology is not known. We have devised a clinical system for mapping conjunctival melanocytic lesions and a system for scoring the histological grade of atypia of conjunctival melanocytic intra-epithelial neoplasia/melanoma in situ. We anticipate that these measures will improve outcomes after treatment of conjunctival melanoma in situ and invasive melanoma.

Keywords: brachytherapy; conjunctiva; conjunctival melanocytic intra-epithelial neoplasi; cryotherapy; grading; melanoma; melanoma in situ; melanosis; mitomycin C; primary acquired melanosis; staging; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.1586/era.09.85

Affiliations: 1: Ocular Oncology Service, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK., Email: bertil@damato.co.uk

Publication date: 2009-09-01

More about this publication?

• Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: Damato, Bertil ;  Coupland, Sarah E

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers